
FDA’s Quiet Withdrawal of Diversity Guidance Stirs Debate on Inclusive Clinical Trials
The FDA’s unexpected withdrawal of a draft guidance aimed at enhancing diversity in clinical trials stirs debate on its commitment to inclusivity, following an executive